Page 12 - Linical Evolution News Today

Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.

A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.

Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

Vedanta Biosciences has obtained fast track designation from the US Food and Drink Administration (FDA) for its live biotherapeutic VE303, a preventative treatment for recurrent Clostridioides difficile infection (CDI).

A single-agent treatment for patients with relapsed or refractory myelodysplastic neoplasms has shown promising results, including overall survival, in a study.

Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.

Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.

The AI-powered search tool will be provided to healthcare professionals to connect patients with potential treatments.